Role of MicroRNAs in Cardiac Remodeling and Heart Failure

Role of MicroRNAs in Cardiac Remodeling and Heart Failure
复制标题

DOI:
10.1007/s10557-011-6289-5
复制
发表时间:
2011-04-01
影响因子:
3.4
通讯作者:
Mann, Douglas L.
Mann, Douglas L.
中科院分区:
医学3区
文献类型:
--
作者:
Topkara, Veli K.;Mann, Douglas L.

文献摘要

被引文献

相似文献

MicroRNA (miRNA) 是内源性、短(类似于 22 个核苷酸)、进化上保守的非编码 RNA,可在转录后水平调节基因表达。最近的证据表明,miRNA 在衰竭心肌中差异表达,并通过靶向控制心脏重塑过程中多种功能(包括心肌细胞肥大、兴奋-收缩耦合、心肌细胞丢失增加和心肌纤维化)的基因,在心力衰竭的进展中发挥重要作用。除了在不良心脏重塑中发挥作用外,miRNA 还有望作为心力衰竭疾病进展的生物标志物,因为它们存在于循环中并具有增强的稳定性。基于 miR 的疗法的进一步开发可能允许调节心力衰竭患者的心脏和/或全身特定 miRNA 水平。在这里,我们总结了目前对 miRNA 在调节心脏重塑过程各个方面的作用的了解,并讨论了它们作为心力衰竭生物标志物和/或治疗靶点的潜在用途。
MicroRNAs (miRNAs) are endogenous, short (similar to 22 nucleotide), evolutionarily conserved, non-coding RNAs that regulate gene expression at the post-transcriptional level. Recent evidence suggests that miRNAs are differentially expressed in the failing myocardium and play an important role in progression of heart failure by targeting genes that govern diverse functions in cardiac remodeling process including myocyte hypertrophy, excitation-contraction coupling, increased myocyte loss, and myocardial fibrosis. In addition to their role in adverse cardiac remodeling, miRNAs hold promise as biomarkers of disease progression in heart failure given their presence in circulation and enhanced stability. Further development of miR-based therapeutics may allow for modulation of cardiac and/or systemic levels of specific miRNAs in patients with heart failure . Here, we summarize current knowledge of miRNAs in relation to their role in regulating various aspects of the cardiac remodeling process and discuss their potential use as biomarkers and/or therapeutic targets in heart failure.